Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas [Phase 1]
Phase 1 safety and preliminary efficacy study of CC-90011 in participants with relapsed/refractory solid tumors and Non-Hodgkin lymphoma. Th…
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma [Phase 1]
A Phase 1 study evaluating OPB-31121 in relapsed or refractory Non-Hodgkin's Lymphoma and Multiple Myeloma has completed.
-
CLINICAL_TRIALS research · 2025-04-16Clinical Trial Update: A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies [Phase 1]
Phase 1 study of APG-2575 by Ascentage Pharma for chronic lymphocytic leukemia and non-Hodgkin lymphoma is currently active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for untreated indolent B-cell non-Hod…
-
CLINICAL_TRIALS research · 2025-04-11Clinical Trial Update: Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma. [NA]
This clinical trial update notes recruitment for a study on optimizing radiation dose in diffuse large B-cell lymphoma, a form of non-Hodgki…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients [Phase 1, Phase 2]
Clinical trial update documenting pharmacokinetics, safety, and tolerability assessment of Abexinostat in Chinese patients with Non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab [Phase 1]
This Phase 1 update describes adverse events and changes in disease state observed in pediatric participants and young adults (ages 18-25) w…
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial of VIP-152 in combination with Venetoclax and Prednisone in relapsed/refractory lymphoid malignancies has completed…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation [Phase 1]
Phase 1 study evaluating itacitinib for prophylaxis of graft-versus-host disease and cytokine release syndrome after T-cell replete haploide…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies [Phase 1]
Phase 1 study evaluating autologous CD19 CAR-T cell therapy SYNCAR-001 with orthogonal IL-2 STK-009 in CD19-positive hematologic malignancie…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors [Phase 2]
A Phase 2 trial evaluating α/β+-T lymphocyte-depleted donor grafts from HLA-mismatched donors in multiple hematologic malignancies was termi…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies [Phase 1]
A Phase 1 clinical study evaluating the CD70-targeted agent CHT101 in relapsed or refractory hematologic malignancies is currently recruitin…
-
EMA approval · 2025-04-03EMA Authorised: MabThera (rituximab) — Roche Registration GmbH
EMA authorised MabThera (rituximab) for multiple indications including Non-Hodgkin lymphoma, rheumatoid arthritis, and chronic lymphocytic l…
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers [Phase 1]
Aplitabart (IGM-8444) Phase 1a/1b study in solid tumors and various hematologic cancers was terminated.
-
CLINICAL_TRIALS research · 2025-03-27Clinical Trial Update: Epcoritamab-CAR T Cells for Large B-cell Lymphomas [Phase 2]
Phase 2 clinical trial evaluating epcoritamab-CAR T cells for large B-cell lymphomas, currently recruiting.
-
FDA approval · 2025-03-26FDA Approved: PLERIXAFOR — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for a generic version of Plerixafor submitted by Eugia US LLC.
-
FDA approval · 2025-03-26FDA Approved: PLERIXAFOR — Supplemental Application (Novadoz Pharmaceuticals LLC)
The FDA approved a supplemental application for Plerixafor filed by Novadoz Pharmaceuticals LLC, related to changes to labeling and/or indic…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL [Phase 1, Phase 2]
The trial evaluating allo GDA-201 natural killer cells for relapsed/refractory B-cell non-Hodgkin lymphoma was terminated, and the results h…
-
CLINICAL_TRIALS research · 2025-03-24Clinical Trial Update: CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) [Phase 1]
A Phase 1 trial evaluating a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy (ANTLER) for relapsed/refractory B-cell non-Hodgkin lymph…
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma
A clinical trial update evaluating the association between fatigue and specific adverse events within the first month after CAR-T cell thera…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors [Phase 1]
Phase 1 trial of KT-333 in adults with refractory lymphomas and solid tumors reports safety, pharmacokinetics, pharmacodynamics, and prelimi…
-
CLINICAL_TRIALS research · 2025-03-17Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Lymphoma [NA]
Clinical trial update for JY231 injection for relapsed or refractory B-cell non-Hodgkin lymphoma; the study status is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-11Clinical Trial Update: Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
A US-based observational lymphoma registry sponsored by Celgene has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-03-10Clinical Trial Update: An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 open-label dose-escalation study evaluating safety, pharmacokinetics, pharmacodynamics, and early clinical activity of GSK3326595 in…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease [Phase 2]
Phase 2 trial evaluating an umbilical cord blood transplant regimen with cyclophosphamide, fludarabine, and total-body irradiation for hemat…